PTOISBIGE (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number		10526518		
	Filing Date		2005-03-03		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Matsu		atsumoto, Seiji		
	Art Unit		1763		
	Examiner Name	Natha	an H. Empie		
	Attorney Docket Number		O1044/20013		

	U.S.PATENTS							Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	of cited Decument		Releva	Columns,Lines wh ant Passages or Re s Appear	ere levant
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap					d button		
				FOREK	GN PA1	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lir where Relevant Passages or Relev Figures Appear	Te
	1	2000-149251	JP			2000-05-30	Toda Hisashi			
	2	11-236242	JP			1999-08-31	Nakamichi Manabi			
	3	10-143858	JP			1998-05-29	Nishimura Yukihiro			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Application First Nam Art Unit Examines

Application Number		10526518		
Filing Date		2005-03-03		
First Named Inventor	Matsu	rmoto, Seiji		
Art Unit		1763		
Examiner Name Natha		n H. Empie		
Attorney Docket Number		O1044/20013		

If you wisl	h to a	dd add	itional Foreign Patent Document citation information please	click the Add buttor	Add	
			NON-PATENT LITERATURE DOCUM	IENTS	Remove	
Examiner Initials*	Examinor Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.					T5
	1					-
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						
Examiner	Examiner Signature Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

1 See Kind Codes of USPTO Patent Documents at www.ISPTO.QQD/ or MPEP 90104. 2 Enter office that issued the document, by the hor-deter code (WIPO Standard ST3.) 2 for Junganese patent documents, the included not not be year of the insight of the Emperor may precede the serial runber of the patent of being of the Emperor may precede the serial runber of the patent of being of the Emperor may precede the serial runber of the patent of

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10526518
Filing Date		2005-03-03
First Named Inventor	Matsu	umoto, Seiji
Art Unit		1763
Examiner Name	Nathan H. Empie	
Attorney Docket Number		O1044/20013

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	of the agradie.						
	Signature	/Frank M. Linguit/	Date (YYYY-MM-DD)	2007-09-14			
	Name/Print	Frank M. Linguiti	Registration Number	32.424			

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.3.2311-4450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.